Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707900 · ClinicalTrials.gov registry record · Phase 1
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02707900 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6 participants.
The verdict
NCT02707900, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this research study is to 1) evaluate the safety of a series of injections with the AGS-004 product in combination with a series of Vorinostat doses and 2) to help scientists evaluate ways of reactivating latent (non-acting) HIV virus and determine if the immune system can be made stronger to eliminate the activated HIV virus.
Interventions
- DRUG Vorinostat
- BIOLOGICAL AGS-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02707900
The ClinicalTrials.gov registry entry for NCT02707900 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT02707900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02707900 about?
NCT02707900 is a clinical study titled "Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection". The purpose of this research study is to 1) evaluate the safety of a series of injections with the AGS-004 product in combination with a series of Vorinostat doses and 2) to help scientists evaluate ways of reactivating latent (non-acting) HIV virus and determine if the immune system can be made str...
What is the current status of trial NCT02707900?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-03. Estimated completion is 2018-07-11.
What interventions are being tested in trial NCT02707900?
The interventions under investigation include: Vorinostat (DRUG), AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02707900?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.